Diaceutics (FRA:7DC) LT-Debt-to-Total-Asset: 0.02 (As of Dec. 2025)

What is Diaceutics LT-Debt-to-Total-Asset?

Diaceutics FRA:7DC -0.61% 91 LT-Debt-to-Total-Asset is 0.02 as of Dec. 2025. GuruFocus rates FRA:7DC with a GF Score™ of 91/100 and a GF Value™ of €2.14 (Modestly Undervalued). The stock has 1 warning sign investors should review.

LT Debt to Total Assets is a measurement representing the percentage of a corporation's assets that are financed with loans and financial obligations lasting more than one year. The ratio provides a general measure of the financial position of a company, including its ability to meet financial requirements for outstanding loans. It is calculated as a company's Long-Term Debt & Capital Lease Obligationdivide by its Total Assets. Diaceutics's long-term debt to total assests ratio for the quarter that ended in Dec. 2025 was 0.02.

Diaceutics's long-term debt to total assets ratio declined from Dec. 2024 (0.02) to Dec. 2025 (0.02). It may suggest that Diaceutics is progressively becoming less dependent on debt to grow their business.

Diaceutics (FRA:7DC) LT-Debt-to-Total-Asset Explanation

LT Debt to Total Asset is a measurement representing the percentage of a corporation's assets that are financed with loans and financial obligations lasting more than one year. The ratio provides a general measure of the financial position of a company, including its ability to meet financial requirements for outstanding loans. A year-over-year decrease in this metric would suggest the company is progressively becoming less dependent on debt to grow their business.

Diaceutics LT-Debt-to-Total-Asset Related Terms

Diaceutics LT-Debt-to-Total-Asset Historical Data

* Premium members only.

The historical data trend for Diaceutics's LT-Debt-to-Total-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Diaceutics LT-Debt-to-Total-Asset Chart

Diaceutics Annual Data

Trend

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

Dec25

LT-Debt-to-Total-Asset

Get a 7-Day Free Trial

0.03

0.02

Diaceutics Semi-Annual Data
	Dec16	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23	Jun24	Dec24	Jun25	Dec25
LT-Debt-to-Total-Asset	Get a 7-Day Free Trial													0.02	0.02	0.02	0.02	0.02

91GF Score

Diaceutics PLC FRA:7DC

LT-Debt-to-Total-Asset is just one metric. See GF Score™, valuation, warning signs, and more.

View Full Analysis

Diaceutics LT-Debt-to-Total-Asset Calculation

Diaceutics's Long-Term Debt to Total Asset Ratio for the fiscal year that ended in Dec. 2025 is calculated as

LT Debt to Total Assets (A: Dec. 2025 )	=	Long-Term Debt & Capital Lease Obligation (A: Dec. 2025 )	/	Total Assets (A: Dec. 2025 )
	=	1.008	/	57.171
	=	0.02

Diaceutics's Long-Term Debt to Total Asset Ratio for the quarter that ended in Dec. 2025 is calculated as

LT Debt to Total Assets (Q: Dec. 2025 )	=	Long-Term Debt & Capital Lease Obligation (Q: Dec. 2025 )	/	Total Assets (Q: Dec. 2025 )
	=	1.008	/	57.171
	=	0.02

Frequently Asked Questions Learn more about LT-Debt-to-Total-Asset →

What does a LT-Debt-to-Total-Asset of 0.02 mean?

Diaceutics (FRA:7DC) has a LT-Debt-to-Total-Asset of 0.02 as of Dec. 2025. Long-term Debt to Total Asset ratio is the ratio of total long-term debt to total assets. View historical data on Diaceutics and its competitors.

Is Diaceutics' LT-Debt-to-Total-Asset too high?

Diaceutics' current LT-Debt-to-Total-Asset is 0.02. Overall, Diaceutics has a GF Score™ of 91/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.

How does Diaceutics' LT-Debt-to-Total-Asset compare to VEEV and BTSG?

Diaceutics' LT-Debt-to-Total-Asset of 0.02 can be compared against companies in the Healthcare Providers & Services industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.

What is a good LT-Debt-to-Total-Asset for a Healthcare Providers & Services company?

A good LT-Debt-to-Total-Asset depends on the Healthcare Providers & Services industry context. However, LT-Debt-to-Total-Asset should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.

What does a high LT-Debt-to-Total-Asset mean?

A high LT-Debt-to-Total-Asset can signal that a stock is expensive relative to its fundamentals. Long-term Debt to Total Asset ratio is the ratio of total long-term debt to total assets. View historical data on Diaceutics and its competitors. Diaceutics's current LT-Debt-to-Total-Asset is 0.02. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.

Is Diaceutics stock overvalued right now?

Based on GuruFocus' analysis, Diaceutics (FRA:7DC) is currently considered Modestly Undervalued. The stock's GF Value™ is €2.14, compared to a current price of €1.64 — trading 23.4% below its estimated fair value. The current LT-Debt-to-Total-Asset is 0.02. Diaceutics' overall GF Score™ is 91/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.

How is LT-Debt-to-Total-Asset calculated?

LT-Debt-to-Total-Asset is calculated from a company's financial statements. For Diaceutics (FRA:7DC), the current LT-Debt-to-Total-Asset is 0.02 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Diaceutics (FRA:7DC) Overvalued in 2026?

Based on GuruFocus' analysis, Diaceutics stock appears to be undervalued. The current stock price of €1.64 is trading 23.4% below its estimated GF Value™ of €2.14. GuruFocus considers Diaceutics to be Modestly Undervalued.

Key valuation signals for FRA:7DC:

LT-Debt-to-Total-Asset: 0.02
GF Value™: €2.14 vs. price of €1.64 (23.4% below fair value)
GF Score™: 91/100 with 1 warning sign

No single metric tells the full story. See the FRA:7DC stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Diaceutics Business Description

Industry Healthcare Healthcare Providers & Services

Comparable Companies LSE:KOO LSE:OPT LSE:MPAL LSE:COG LSE:RENX LSE:FDBK LSE:IBAI AQSE:DXSP LSE:TRLS LSE:CRW VEEV ASX:PME BTSG TEM HQY TSE:2413 HNGE TXG DOCS WAY

Other Exchanges DIUXF:USA DXRX:UK

Address Dataworks at Kings Hall Health & Wellbeing Park, First Floor, Building Two, County Antrim, Belfast, GBR, BT9 6GW

Website https://www.diaceutics.com

Diaceutics PLC is a data analytics and implementation services company that services the pharmaceutical industry. It provides integrated commercialization solutions that help biopharma companies maximize patient access, accelerate uptake, and improve the lifetime value of their therapies. The group's services span the full commercial lifecycle, from pre-launch ideas through to mature brand optimization, delivered through an integrated combination of data, technology, and expertise. Its DXRX Data Solutions include DXRX Signal, DXRX Physician Segmentation, DXRX Lab Segmentation, and DXRX Disease Testing Rate Tracker. Geographical market by customer location in the UK, North America, Europe, Asia, and the rest of the world.

91GF Score

Get the complete analysis for FRA:7DC

LT-Debt-to-Total-Asset is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€1.64

Price

€2.14

GF Value

View FRA:7DC Analysis

See LT-Debt-to-Total-Asset data for all stocks →